Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 0 · 0%

Casirivimab/imdevimab vs usual care

Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.94 [0.87, 1.02]
1 study · 9785 participants
Moderate

Casirivimab/imdevimab vs usual care

Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Clinical progression: IMV or death (≥ 7 WHO scale) · hospitalised individuals with COVID‐19 (moderate to severe disease)

Casirivimab/imdevimab showed no clear difference in clinical progression: need for IMV or death (WHO ≥ 7) compared with usual care alone (moderate certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.96 [0.9, 1.04]
1 study · 9198 participants
Moderate

Casirivimab/imdevimab vs usual care

Quality of life · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Hospital discharge alive by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Casirivimab/imdevimab showed no clear difference in hospital discharge alive by day 30 compared with usual care alone (moderate certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 1.01 [0.98, 1.04]
1 study · 9785 participants
Moderate

Casirivimab/imdevimab vs usual care

Grades 3 and 4 adverse events · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs usual care

Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found